Advisory Research Inc Crispr Therapeutics Ag Transaction History

Advisory Research Inc

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 13, 2024	BUY	$38.62 - $72.18 $214,727 - $401,320	5,560 New	5,560 $348,000
Q3 2021 Nov 12, 2021	SELL	$110.2 - $156.64 $352,750 - $501,404	-3,201 Closed	0 $0
Q2 2021 Aug 16, 2021	BUY	$100.84 - $161.89 $322,788 - $518,209	3,201 New	3,201 $518,000
Q1 2021 May 12, 2021	SELL	$110.72 - $210.04 $824,199 - $1.56 Million	-7,444 Closed	0 $0
Q4 2020 Feb 12, 2021	SELL	$79.67 - $173.23 $491,643 - $1.07 Million	-6,171 Reduced 45.33%	7,444 $1.14 Million
Q3 2020 Nov 12, 2020	SELL	$78.5 - $100.64 $73,005 - $93,595	-930 Reduced 6.39%	13,615 $1.14 Million
Q2 2020 Aug 13, 2020	BUY	$38.5 - $76.05 $559,982 - $1.11 Million	14,545 New	14,545 $1.07 Million

485

57.5M

1.09M

1.9M

Ticker CRSP
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 78,009,296
Market Cap $3.12B
Description
CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious diseases using its proprietary Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. Its CRISPR/Cas9 is a gene editing technology that allows for precise directed changes to genomic DNA....

Get notified when there are updates to the investment portfolio of Advisory Research Inc, based on Form 13F filings with the SEC.

Stay updated on Advisory Research Inc with notifications on news.